<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00961961</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH080097</org_study_id>
    <secondary_id>R01MH080097</secondary_id>
    <secondary_id>R01MH080098</secondary_id>
    <nct_id>NCT00961961</nct_id>
  </id_info>
  <brief_title>Prevention of Relapse &amp; Recurrence of Bipolar Depression</brief_title>
  <official_title>Prevention of Relapse &amp; Recurrence of Bipolar Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the long-term use of combined&#xD;
      antidepressant plus mood stabilizer therapy is superior to mood stabilizer therapy alone in&#xD;
      preventing the relapse and recurrence of bipolar depression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recurrence of Bipolar I (BP I) major depressive episode (MDE), is now recognized as a major&#xD;
      mental health problem. Recurrent BP I MDE is a disorder with no satisfactory therapy, and its&#xD;
      treatment remains a challenge to clinicians. To date, initial and long-term therapy of BP I&#xD;
      MDE has been based on un-validated practice guidelines. These guidelines recommend limiting&#xD;
      antidepressant drug (AD) use during initial therapy of BP I MDE, and completely avoiding AD&#xD;
      use during long-term therapy. There is, however, no empirical evidence to suggest that mood&#xD;
      stabilizer (MS) monotherapy is superior to combined MS plus AD therapy in preventing&#xD;
      recurrent BP I MDE. Nor is there evidence to suggest that long-term MS plus AD therapy&#xD;
      results in more manic switch episodes. We present evidence that AD-induced mania during&#xD;
      long-term therapy of BP I MDE has been over-estimated, and that long-term use of MS plus AD&#xD;
      therapy may be superior to MS therapy alone in preventing recurrent BP I MDE. In this study,&#xD;
      we will ask: &quot;Does continuation therapy with combined lithium plus fluoxetine result in fewer&#xD;
      MDE relapses and recurrences vs. lithium monotherapy?&quot; To answer this question, patients with&#xD;
      BP I MDE will receive combined lithium plus fluoxetine therapy for 8 weeks. Responders who&#xD;
      stay well for an additional 4 weeks of consolidation therapy will then be randomized to&#xD;
      double-blind continuation therapy with either (i) combined lithium plus fluoxetine, or (ii)&#xD;
      lithium alone (following fluoxetine taper and discontinuation) for an additional 50 weeks. We&#xD;
      hypothesize that long-term lithium plus fluoxetine therapy will result in fewer MDE relapses&#xD;
      and recurrences vs. lithium monotherapy. We will also ask: &quot;What is the relative safety,&#xD;
      tolerability, and frequency of syndromal and sub-syndromal manic, hypomanic, and mixed state&#xD;
      conversions during continuation treatment with combined lithium plus fluoxetine vs. lithium&#xD;
      monotherapy?&quot; To answer this question, we will measure: the frequency, severity, and duration&#xD;
      of syndromal and sub-syndromal manic, hypomanic, and mixed state conversions; frequency,&#xD;
      severity, and duration of treatment-emergent adverse events; frequency of treatment&#xD;
      discontinuation; time to onset of first syndromal and sub-syndromal conversion event; time to&#xD;
      first treatment intervention of each syndromal and sub-syndromal conversion event; and, time&#xD;
      to onset of increase in suicidal ideation event. We hypothesize that lithium plus fluoxetine&#xD;
      therapy will result in a similar frequency of syndromal and sub-syndromal conversion events,&#xD;
      and a similar frequency of treatment-emergent adverse events. We further hypothesize that&#xD;
      lithium plus fluoxetine therapy will result in fewer suicide ideation events and fewer study&#xD;
      discontinuations vs. lithium monotherapy. We believe that the results of this trial may have&#xD;
      an important public health impact on the current practice guidelines for treating BP I MDE.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2009</start_date>
  <completion_date type="Actual">September 1, 2016</completion_date>
  <primary_completion_date type="Actual">September 1, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Relapse of Major Depressive Episode Within 1 Year</measure>
    <time_frame>1 year</time_frame>
    <description>Patients who were randomized to one of the Phase II conditions were interviewed once each month. If they met criteria for a relapse of a Major Depressive Episode, this was considered the study outcome. If they participated for the full year of Phase II without a documented relapse, they were considered a completer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Onset of a Manic Episode Within 1 Year</measure>
    <time_frame>1 Year</time_frame>
    <description>Onsets of a manic episodes were ascertained with the clinician-rated Young Mania Rating Scale (YMRS). The YMRS covers 11 symptom groups over the previous 48 hours. Four of the items are rated on a scale from 0 to 4; the other 4 are rated on a scale of 0 to 8. A score of 12 or above indicates a manic episode.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Onset of a Hypomanic Episode Within 1 Year</measure>
    <time_frame>1 Year</time_frame>
    <description>Onsets of a hypomanic episodes were ascertained with the clinician-rated Hypomania Interview Guide and associated scoring rules.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Onset of a Sub-Syndromal Mood Conversion Episode Within 1 Year</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">177</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Lithium plus Fluoxetine Phase I</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants were started in this arm. Those who met criteria for entry into Phase II were then randomized to one of the two Phase II arms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lithium plus Placebo Phase I</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No participants began their participation on Lithium plus Placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lithium plus Fluoxetine Phase II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who responded to Lithium plus Fluoxetine in Phase I and were randomized to continue on both compounds.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lithium plus Placebo Phase II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients who responded to Lithium plus Fluoxetine in Phase I and were randomized to switch from Fluoxetine to placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium / Fluoxetine</intervention_name>
    <description>Individualized Daily Dosage</description>
    <arm_group_label>Lithium plus Fluoxetine Phase I</arm_group_label>
    <arm_group_label>Lithium plus Fluoxetine Phase II</arm_group_label>
    <other_name>Lithium Carbonate / Prozac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium / Placebo</intervention_name>
    <description>Individualized Daily Dosage</description>
    <arm_group_label>Lithium plus Placebo Phase I</arm_group_label>
    <arm_group_label>Lithium plus Placebo Phase II</arm_group_label>
    <other_name>Lithium Carbonate / Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men/women (all races and ethnicity)&#xD;
&#xD;
          -  Age at least 18 years old&#xD;
&#xD;
          -  Bipolar Type I Disorder&#xD;
&#xD;
          -  Current Major Depressive Episode&#xD;
&#xD;
          -  Able to understand and provide signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current alcohol or drug abuse&#xD;
&#xD;
          -  Alcohol or drug dependence within 3 months&#xD;
&#xD;
          -  Allergic to Fluoxetine or Lithium&#xD;
&#xD;
          -  Unstable medical condition (e.g., uncontrolled thyroid, renal, cardiovascular disease)&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Women of child-bearing potential unwilling to use a medically acceptable form of&#xD;
             contraception&#xD;
&#xD;
          -  Actively suicidal&#xD;
&#xD;
          -  Requiring hospitalization&#xD;
&#xD;
          -  Use of medication contraindicated with lithium or fluoxetine&#xD;
&#xD;
          -  Unable to participate in a year-long trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J. DeRubeis, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John M Zajecka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Depression Research Unit</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-3309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://web.sas.upenn.edu/derubeis/</url>
    <description>DeRubeis Lab Web Page</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 18, 2009</study_first_submitted>
  <study_first_submitted_qc>August 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2009</study_first_posted>
  <results_first_submitted>August 26, 2020</results_first_submitted>
  <results_first_submitted_qc>September 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2020</results_first_posted>
  <last_update_submitted>September 23, 2020</last_update_submitted>
  <last_update_submitted_qc>September 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bipolar Disorder</keyword>
  <keyword>Manic Depression</keyword>
  <keyword>Major Depressive Episode</keyword>
  <keyword>Mania</keyword>
  <keyword>Hypomania</keyword>
  <keyword>Long Term Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lithium Carbonate</mesh_term>
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Phase I was an open label treatment, of Lithium and Fluoxetine, of all enrolled patients.&#xD;
Those who met criteria for response after 12 weeks were randomized to one of two Phase II (double-blinded) arms:&#xD;
Lithium plus Fluoxetine&#xD;
Lithium plus Placebo</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lithium Plus Fluoxetine Phase I</title>
          <description>Lithium / Fluoxetine: Individualized Daily Dosage</description>
        </group>
        <group group_id="P2">
          <title>Lithium Plus Placebo Phase I</title>
          <description>This is a placeholder arm. No participants were given Placebo in Phase I.</description>
        </group>
        <group group_id="P3">
          <title>Lithium Plus Fluoxetine Phase II</title>
          <description>One of the two randomly assigned groups, each of which continued on Lithium Double-blind assignment to continue on Fluoxetine (this group)</description>
        </group>
        <group group_id="P4">
          <title>Lithium Plus Placebo Phase II</title>
          <description>One of the two randomly assigned groups, each of which continued on Lithium Double-blind assignment to switch from Fluoxetine to Placebo (this group)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase I</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="177"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">This is a Phase I category. Not relevant in Phase II.</participants>
                <participants group_id="P2" count="0">This is a Phase I category. Not relevant in Phase II.</participants>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants were assessed prior to entering the open label phase of the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Lithium Plus Fluoxetine Phase I</title>
          <description>All eligible and consenting participants began in this open phase. Therefore baseline characteristics are only relevant for this category.</description>
        </group>
        <group group_id="B2">
          <title>Lithium Plus Placebo Phase I</title>
          <description>No participant was begun on Placebo. Lithium Plus Placebo was a real condition only after randomization, in Phase II. Baseline characteristics for all participants are listed under Lithium plus Fluoxetine Phase I.</description>
        </group>
        <group group_id="B3">
          <title>Lithium Plus Fluoxetine Phase II</title>
          <description>This is a subset of patients whose baseline characteristics are listed under Lithium plus Fluoxetine Phase I.</description>
        </group>
        <group group_id="B4">
          <title>Lithium Plus Placebo Phase II</title>
          <description>This is a subset of patients whose baseline characteristics are listed under Lithium plus Fluoxetine Phase I.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="177"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="0"/>
            <count group_id="B5" value="177"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="175"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="175"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B5" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Relapse of Major Depressive Episode Within 1 Year</title>
        <description>Patients who were randomized to one of the Phase II conditions were interviewed once each month. If they met criteria for a relapse of a Major Depressive Episode, this was considered the study outcome. If they participated for the full year of Phase II without a documented relapse, they were considered a completer.</description>
        <time_frame>1 year</time_frame>
        <population>The analyses are relevant only during Phase II. The comparisons are between those assigned to one of the two randomized Phase II conditions.</population>
        <group_list>
          <group group_id="O1">
            <title>Lithium Plus Fluoxetine Phase I</title>
            <description>The outcome measures, including this one, are only relevant in Phase II. Thus there will be zeroes in this category.</description>
          </group>
          <group group_id="O2">
            <title>Lithium Plus Placebo Phase I</title>
            <description>The outcome measures, including this one, are only relevant in Phase II. Thus there will be zeroes in this category.</description>
          </group>
          <group group_id="O3">
            <title>Lithium Plus Fluoxetine Phase II</title>
            <description>Participants randomized to this condition remained on active medications. However, the fluoxetine pills were made to look like the placebo pills, to maintain the double-blind.</description>
          </group>
          <group group_id="O4">
            <title>Lithium Plus Placebo Phase II</title>
            <description>Participants randomized to this condition were switched from fluoxetine to placebo. However, the placebo pills were made to look like the fluoxetine pills, to maintain the double-blind.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Relapse of Major Depressive Episode Within 1 Year</title>
          <description>Patients who were randomized to one of the Phase II conditions were interviewed once each month. If they met criteria for a relapse of a Major Depressive Episode, this was considered the study outcome. If they participated for the full year of Phase II without a documented relapse, they were considered a completer.</description>
          <population>The analyses are relevant only during Phase II. The comparisons are between those assigned to one of the two randomized Phase II conditions.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Onset of a Manic Episode Within 1 Year</title>
        <description>Onsets of a manic episodes were ascertained with the clinician-rated Young Mania Rating Scale (YMRS). The YMRS covers 11 symptom groups over the previous 48 hours. Four of the items are rated on a scale from 0 to 4; the other 4 are rated on a scale of 0 to 8. A score of 12 or above indicates a manic episode.</description>
        <time_frame>1 Year</time_frame>
        <population>This and other outcomes are only relevant in the double-blind Phase II of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Lithium Plus Fluoxetine Phase I</title>
            <description>This is not a relevant category for this outcome. This outcome is only assessed in Phase II.</description>
          </group>
          <group group_id="O2">
            <title>Lithium Plus Placebo Phase I</title>
            <description>This is not a relevant category for this outcome. This outcome is only assessed in Phase II.</description>
          </group>
          <group group_id="O3">
            <title>Lithium Plus Fluoxetine Phase II</title>
            <description>Includes participants who completed Phase I and were assigned randomly to continue on their medications in Phase II (double-blind, as the fluoxetine and placebo were identical in appearance.</description>
          </group>
          <group group_id="O4">
            <title>Lithium Plus Placebo Phase II</title>
            <description>Includes participants who completed Phase I and were assigned randomly to switch from fluoxetine to placebo in Phase II (double-blind, as the fluoxetine and placebo were identical in appearance).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Onset of a Manic Episode Within 1 Year</title>
          <description>Onsets of a manic episodes were ascertained with the clinician-rated Young Mania Rating Scale (YMRS). The YMRS covers 11 symptom groups over the previous 48 hours. Four of the items are rated on a scale from 0 to 4; the other 4 are rated on a scale of 0 to 8. A score of 12 or above indicates a manic episode.</description>
          <population>This and other outcomes are only relevant in the double-blind Phase II of the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Onset of a Hypomanic Episode Within 1 Year</title>
        <description>Onsets of a hypomanic episodes were ascertained with the clinician-rated Hypomania Interview Guide and associated scoring rules.</description>
        <time_frame>1 Year</time_frame>
        <population>These are the patients who were randomly assigned, after responding to the medications provided in Phase I, to either remain on the same regime or have their fluoxetine switched to placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Lithium Plus Fluoxetine Phase I</title>
            <description>All participants began with both medications in Phase I, which led into Phase II.</description>
          </group>
          <group group_id="O2">
            <title>Lithium Plus Placebo Phase I</title>
            <description>No participant was on placebo in Phase I. Only during Phase II.</description>
          </group>
          <group group_id="O3">
            <title>Lithium Plus Fluoxetine Phase II</title>
            <description>Participants randomized to this condition remained on active medications. However, the fluoxetine pills were made to look like the placebo pills, to maintain the double-blind.</description>
          </group>
          <group group_id="O4">
            <title>Lithium Plus Placebo Phase II</title>
            <description>Participants randomized to this condition were switched from fluoxetine to placebo. However, the fluoxetine pills were made to look like the placebo pills, to maintain the double-blind.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Onset of a Hypomanic Episode Within 1 Year</title>
          <description>Onsets of a hypomanic episodes were ascertained with the clinician-rated Hypomania Interview Guide and associated scoring rules.</description>
          <population>These are the patients who were randomly assigned, after responding to the medications provided in Phase I, to either remain on the same regime or have their fluoxetine switched to placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Onset of a Sub-Syndromal Mood Conversion Episode Within 1 Year</title>
        <time_frame>1 Year</time_frame>
        <population>This was not a diagnosis that was recognized widely in the profession. Procedures for ascertaining such episodes were not consistent across the two performance sites. As a consequence the data obtained to document this outcome were unreliable.</population>
        <group_list>
          <group group_id="O1">
            <title>Lithium Plus Fluoxetine</title>
            <description>Lithium / Fluoxetine: Individualized Daily Dosage</description>
          </group>
          <group group_id="O2">
            <title>Lithium Plus Placebo</title>
            <description>Lithium / Placebo: Individualized Daily Dosage</description>
          </group>
          <group group_id="O3">
            <title>Lithium Plus Fluoxetine Phase II</title>
            <description>Participants randomized to this condition remained on active medications. However, the fluoxetine pills were made to look like the placebo pills, to maintain the double-blind.</description>
          </group>
          <group group_id="O4">
            <title>Lithium Plus Placebo Phase II</title>
            <description>Participants randomized to this condition remained on active medications. However, the fluoxetine pills were made to look like the placebo pills, to maintain the double-blind.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Onset of a Sub-Syndromal Mood Conversion Episode Within 1 Year</title>
          <population>This was not a diagnosis that was recognized widely in the profession. Procedures for ascertaining such episodes were not consistent across the two performance sites. As a consequence the data obtained to document this outcome were unreliable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>15 months</time_frame>
      <desc>All events were noted during the first phase of the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lithium Plus Fluoxetine Phase I</title>
          <description>This is the condition that all participants started in. They were given Lithium plus Fluoxetine and, if they responded, they were asked to accept random assignment to Phase II.</description>
        </group>
        <group group_id="E2">
          <title>Lithium Plus Placebo Phase I</title>
          <description>No one was on placebo in Phase I.</description>
        </group>
        <group group_id="E3">
          <title>Lithium Plus Fluoxetine Phase II</title>
          <description>These are the patients randomly assigned to stay on the fluoxetine in Phase II.</description>
        </group>
        <group group_id="E4">
          <title>Lithium Plus Placebo Phase II</title>
          <description>These are the patients randomly assigned to switch to placebo from fluoxetine in Phase II.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Unable to swallow pills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalized for dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lethargy, cognitive dulling</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Tremors</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide ideation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Acute mood disturbance</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hospitalized for overdose of benzodiazepines</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hospitalized for acute alcohol abuse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hospitalized for acute substance abuse</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Robert J. DeRubeis</name_or_title>
      <organization>UPenn</organization>
      <phone>215-573-5804</phone>
      <email>derubeis@psych.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

